1983
DOI: 10.1055/s-2007-1021488
|View full text |Cite
|
Sign up to set email alerts
|

Sclerotherapy of Esophageal Varices: Acute Arrest of Gastrointestinal Hemorrhage or Long-term Therapy?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

1986
1986
2000
2000

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 54 publications
(17 citation statements)
references
References 0 publications
0
17
0
Order By: Relevance
“…Endoscopic injection sclerotherapy (EIS) is widely used; however, many endoscopists have been performing solely topical injections under an endoscopic monitor only [1, 2]. This method tends to be inferior to endoscopic variceal ligation [3]because few endoscopists can inject sclerosant intravariceally into the blood supply accurately.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Endoscopic injection sclerotherapy (EIS) is widely used; however, many endoscopists have been performing solely topical injections under an endoscopic monitor only [1, 2]. This method tends to be inferior to endoscopic variceal ligation [3]because few endoscopists can inject sclerosant intravariceally into the blood supply accurately.…”
Section: Discussionmentioning
confidence: 99%
“…The first method treats only the esophageal varices [1, 2, 3], and the second treats the varices along with their blood supply [4, 5, 6]. We have used the latter method, known as endoscopic embolization (EE).…”
Section: Introductionmentioning
confidence: 99%
“…Group I1 comprised 13 patients in whom the source of bleeding before initiation of treatment was gastric or esophageal varices. polidocanol in five patients [intra-and paravariceally, according to the method of Soehendra et al (12)]. Endoscopic examinations were systematically performed 1 week and 1 month after obturation of all varices.…”
Section: Selection Of Patientsmentioning
confidence: 99%
“…They can be divided into those occurring at the site of injection (mostly ulcerations and esophageal fibrosis [20]) and into those originating from injection and systemic dissemination of the sclerosant (mostly fever, bacteremia [72,76], or pulmonary side effects [32,52,71]). In prospective therapeutic clinical trials [38,47,58,73,77,78,[87][88][89]94] fatal complications ranged between 0% and 13% (median 2.5%), mostly caused by perforation of the esophagus, aspiration pneumonia, and bleeding esophageal ulcers. Although the risk of fatal complications is supposed to be lower in patients undergoing elective sclerotherapy, it has to be kept in mind that 1% to 2% of the patients may die by endoscopic prophylaxis.…”
Section: Prophylactic Sclerotherapymentioning
confidence: 99%